Brind.
  1. Immunic, Inc is developing and testing vidofludimus calcium, a lead drug candidate, showing potential to address key drivers of multiple sclerosis disease progression.

Erik Lundgren joins Immunic as CEO, bringing experience from Genentech and leadership roles at Roche.

3 reports, 3 independent Updated May 27
Gone quiet Reached 3 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Erik Lundgren joins Immunic as CEO, bringing experience from Genentech and leadership roles at Roche.

Who's involved

What this event is mainly about
Hoffmann-La RocheErik Lundgren

Keep exploring

Part of

Immunic, Inc is developing and testing vidofludimus calcium, a lead drug candidate, showing potential to address key drivers of multiple sclerosis disease progression. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped